Abstract:Background: The overall objective of the present study is to extend our understanding of the clinical phenotype and underlying mechanism of a newly discovered cardiac arrhythmia syndrome through a multicenter study. Gain-of-function mutations in the cardiac Ca 2+ release channel (RyR2 [ryanodine receptor 2]) cause catecholaminergic polymorphic ventricular tachycardia, whereas loss-of-function RyR2 mutations are linked to a new cardiac arrhythmia disorder termed Ca 2+ -release deficiency syndrome (CRDS). Catecholaminergic polymorphic ventricular tachycardia is an inherited arrhythmia disorder characterized by stress-induced bidirectional and polymorphic ventricular tachyarrhythmias and is routinely diagnosed by using exercise stress testing. Conversely, RyR2-CRDS is characterized by ventricular arrhythmias and sudden cardiac death but a negative exercise stress testing for catecholaminergic polymorphic ventricular tachycardia. There are currently no clinical diagnostic tests for CRDS and affected patients may manifest with sudden cardiac death as their first symptom. In the absence of effective clinical diagnostic tools, in vitro functional characterization of associated RyR2 mutations provides an alternative means to identify potential cases of CRDS. Methods: We searched for patients presenting with phenotypes compatible with CRDS that have RyR2 mutations and performed in vitro functional characterization. Results: We found that 3 novel (G570D, R4147K, and A4203V) and 2 previously reported (M4109R and A4204V) RyR2 mutations associated with CRDS phenotypes markedly reduced caffeine-induced Ca 2+ release and store overload-induced Ca 2+ release. We also characterized 2 additional loss-of-function RyR2 mutations previously reported (Q3925E and L4769S) that are located in the central and channel pore-forming domains critical for Ca 2+ activation and channel gating. Q3925E was identified through postmortem genetic testing in an individual who died suddenly, while L4769S is a variant of uncertain significance reported in ClinVar, suggesting that RyR2 CRDS may be under detected. Conclusions: These findings provide further support for the existence of an emerging RyR2 loss-of-function associated arrhythmia syndrome (CRDS) and shed new insights into the disease mechanism.

Enhanced Cytosolic Ca2+ Activation Underlies a Common Defect of Central Domain Cardiac Ryanodine Receptor Mutations Linked to Arrhythmias*

Enhanced Basal Activity of a Cardiac Ca2+ Release Channel (ryanodine Receptor) Mutant Associated with Ventricular Tachycardia and Sudden Death.

Enhanced Store Overload–Induced Ca 2+ Release and Channel Sensitivity to Luminal Ca 2+ Activation Are Common Defects of RyR2 Mutations Linked to Ventricular Tachycardia and Sudden Death

Characterization of a Novel Mutation in the Cardiac Ryanodine Receptor That Results in Catecholaminergic Polymorphic Ventricular Tachycardia

Loss of Luminal Ca 2+ Activation in the Cardiac Ryanodine Receptor is Associated with Ventricular Fibrillation and Sudden Death

RyR 2 Mutations Linked to Ventricular Tachycardia and Sudden Death Reduce the Threshold for Store-Overload-induced Ca 2 Release ( SOICR )

Functional Consequence of Protein Kinase A-dependent Phosphorylation of the Cardiac Ryanodine Receptor: Sensitization of Store Overload-Induced Ca2+ Release.

Simulation of the Effect of Rogue Ryanodine Receptors on a Calcium Wave in Ventricular Myocytes with Heart Failure.

Endoplasmic Reticulum Ca2+ Measurements Reveal That the Cardiac Ryanodine Receptor Mutations Linked to Cardiac Arrhythmia and Sudden Death Alter the Threshold for Store-Overload-induced Ca2+ Release.

The Central Domain of Cardiac Ryanodine Receptor Governs Channel Activation, Regulation, and Stability.

RyR2 disease mutations at the C-terminal domain intersubunit interface alter closed-state stability and channel activation

Crystal Structure of Cardiac Ryanodine Receptor N-Terminal Region Contains Unique Anion Binding Site Targeted by Disease-Associated Mutations

Reduced Threshold for Store Overload-Induced Ca2+ Release is a Common Defect of RyR1 Mutations Associated with Malignant Hyperthermia and Central Core Disease.

The Cardiac Ryanodine Receptor N-Terminal Region Contains an Anion Binding Site That is Targeted by Disease Mutations

A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia

Human RyR2 (ryanodine Receptor 2) Loss-of-Function Mutations

Increased Ca2+ Transient Underlies RyR2-Related Left Ventricular Noncompaction

Abnormal Ca2+ Homeostasis, Atrial Arrhythmogenesis, and Sinus Node Dysfunction in Murine Hearts Modeling RyR2 Modification

Structural Insight into Ryanodine Receptor Channelopathies

Structural basis for ryanodine receptor type 2 leak in heart failure and arrhythmogenic disorders

Identification of Loss-of-function RyR2 Mutations Associated with Idiopathic Ventricular Fibrillation and Sudden Death